Koh Jung Hee, Lee Saseong, Kim Hyun-Sook, Lee Kyuheon, Lee Chang Seop, Yoo Seung-Ah, Lee Naeun, Kim Wan-Uk
Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Center for Integrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Seoul 06591, Korea.
J Clin Med. 2020 Oct 29;9(11):3499. doi: 10.3390/jcm9113499.
Rheumatoid arthritis (RA) disease activity fluctuates over time. The disease activity score 28 (DAS28) is a widely used and validated scoring system for assessing RA activity; however, it requires time and expertise. This study aimed to develop a new molecular assay capable of rapidly and objectively assessing RA activity. We used a rapid immuno-assay system (FREND™) to measure soluble CD14 (sCD14) levels, which reflect the DAS28. SCD14 concentrations in urine and serum of RA patients were measured, and RA activity and responses to anti-rheumatic drugs were examined at baseline and after 6 months. FREND™ quantified sCD14 levels in a drop of serum and urine accurately and within 5 min. Serum sCD14 concentrations and its changes correlated well with disease activity and treatment responses, and the results were comparable to C-reactive protein. The new composite indices, including the DAS28 and simplified DAS, better detected RA activity than a single sCD14 value and correlated strongly with the DAS28. These indices exhibited excellent diagnostic performance for discriminating a good response 6 months after treatment. We developed a new system for assessing RA activity and therapeutic outcome within 5 min. CD14-based composite indices may have utility for accurate and frequent monitoring of RA status.
类风湿关节炎（RA）的疾病活动随时间波动。疾病活动评分28（DAS28）是一种广泛使用且经过验证的用于评估RA活动的评分系统；然而，它需要时间和专业知识。本研究旨在开发一种能够快速、客观地评估RA活动的新分子检测方法。我们使用快速免疫检测系统（FREND™）来测量可溶性CD14（sCD14）水平，其反映DAS28。测量了RA患者尿液和血清中的sCD14浓度，并在基线和6个月后检查了RA活动及对抗风湿药物的反应。FREND™能在5分钟内准确量化一滴血清和尿液中的sCD14水平。血清sCD14浓度及其变化与疾病活动和治疗反应密切相关，结果与C反应蛋白相当。包括DAS28和简化DAS在内的新综合指标比单一的sCD14值能更好地检测RA活动，且与DAS28密切相关。这些指标在鉴别治疗6个月后的良好反应方面表现出优异的诊断性能。我们开发了一种在5分钟内评估RA活动和治疗结果的新系统。基于CD14的综合指标可能有助于准确、频繁地监测RA状态。
